Results 21 to 30 of about 1,494,935 (289)

Structure-guided design of pure orthosteric inhibitors of αIIbβ3 that prevent thrombosis but preserve hemostasis

open access: yesNature Communications, 2020
Current inhibitors of platelet integrin αIIbβ3 cause excessive bleeding, which limited their clinical use in cardiac patients. Here the authors design pure orthosteric αIIbβ3 inhibitors that prevent platelet aggregation and thrombosis without causing ...
Brian D. Adair   +9 more
doaj   +1 more source

AZAPROSTANOIC ACIDS AS INHIBITORS OF PLATELET AGGREGATION.

open access: yes, 1978
AZAPROSTANOIC ACIDS AS INHIBITORS OF PLATELET ...
STEVEN EDWARD. ENKE (7993676)
core   +4 more sources

Platelet aggregometry assay for evaluating the effects of platelet agonists and antiplatelet compounds on platelet function in vitro

open access: yesMethodsX, 2019
Platelet aggregometry assays are generally used for the analysis of platelet function but can also be adapted for further research and therapy focused applications.
Alexandros Tsoupras   +2 more
doaj   +1 more source

Comparison of the GPVI inhibitors losartan and honokiol

open access: yesPlatelets, 2020
Losartan and honokiol are small molecules which have been described to inhibit aggregation of platelets by collagen. Losartan has been proposed to block clustering of GPVI but not to affect binding of collagen. Honokiol has been reported to bind directly
Marie-Blanche Onselaer   +9 more
doaj   +1 more source

Effects of the Btk-Inhibitors Remibrutinib (LOU064) and Rilzabrutinib (PRN1008) With Varying Btk Selectivity Over Tec on Platelet Aggregation and in vitro Bleeding Time

open access: yesFrontiers in Cardiovascular Medicine, 2021
Background: Bruton tyrosine kinase inhibitors (BTKi) are used in B-cell malignancies and in development against various autoimmune diseases. Since Btk is also involved in specific pathways of platelet activation, BTKi might be considered to target ...
Rundan Duan   +10 more
doaj   +1 more source

PLATELET AGGREGATION INHIBITORS [PDF]

open access: yes, 2023
Peptides and cyclized analogs thereof that are useful as platelet aggregation inhibitors in the treatment of cardiac disease, including acute coronary syndrome are ...

core  

Quercetin inhibits collagen-stimulated platelet activation through inhibition of multiple components of the glycoprotein VI signaling pathway [PDF]

open access: yes, 2003
Background: The regulation of platelet function by pharmacological agents that modulate platelet signaling haspharmacolo proven a successful approach to the prevention of thrombosis.
Cicmil, M   +23 more
core   +1 more source

Platelet interaction with bioactive lipids formed by mild oxidation of low-density lipoprotein [PDF]

open access: yes, 2006
Oxidation of low-density lipoprotein (LDL) generates pro-inflammatory and pro-thrombotic mediators that play a crucial role in cardiovascular and inflammatory diseases.
Wolfgang Siess, Siess, Wolfgang
core   +1 more source

Degradation mechanism of the von Willebrand factor A2 domain by nattokinase

open access: yesFEBS Letters, EarlyView.
Nattokinase, a natto‐derived protease, exhibits potent antithrombotic effects. This study demonstrates that nattokinase directly cleaves the von Willebrand factor (vWF) A2 domain in vitro. Unlike the native regulator ADAMTS13, nattokinase degrades folded vWF independently of shear stress.
Ryuichi Hyakumoto   +3 more
wiley   +1 more source

ABL kinase‐dependent phosphorylation of SH proteins promotes their direct interaction with CRK family SH2 domains

open access: yesFEBS Letters, EarlyView.
CT10 regulator of kinase (CRK) and CRK‐Like (CRKL) are signaling adaptors driving cell adhesion, motility, differentiation, and proliferation. SH2‐domain containing (SH) proteins are enriched in YXXP motifs which when phosphorylated create preferred binding sites for CRK family SH2 domains.
Phoebe M. Cousens   +8 more
wiley   +1 more source

Home - About - Disclaimer - Privacy